We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Estimating the threat posed by prostate cancer.
- Authors
Albertsen, Peter C.
- Abstract
While the ProtecT trial data offer a reasonable approximation of clinical practice, the ProtecT patient cohort differs from contemporary North American patients who likely have had several PSA tests prior to the one that prompted a prostate biopsy, and from contemporary UK patients who now undergo biopsy as a result of a lesion seen on MRI. PSA testing preferentially identifies men with low-grade disease, primarily because low-grade disease is much more common than high-grade disease. The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression.
- Subjects
PROSTATE cancer; PROSTATE biopsy; WATCHFUL waiting
- Publication
BJU International, 2020, Vol 125, Issue 4, p480
- ISSN
1464-4096
- Publication type
Article
- DOI
10.1111/bju.15021